TY - STD TI - Act to reorganize the pharmaceuticals’ market in the SHI system (Arzneimittelneuordnungsgesetz-AMNOG) [Internet]. 2010. Available from: http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl110s2262.pdf%27%5D__1431036981006. UR - http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl110s2262.pdf%27%5D__1431036981006 ID - ref1 ER - TY - JOUR AU - Gerber, A. AU - Stock, S. AU - Dintsios, C. M. PY - 2011 DA - 2011// TI - Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? JO - PharmacoEconomics. VL - 29 UR - https://doi.org/10.2165/11592580-000000000-00000 DO - 10.2165/11592580-000000000-00000 ID - Gerber2011 ER - TY - JOUR AU - Dintsios, C. M. AU - Schlenkrich, S. PY - 2018 DA - 2018// TI - INDUSTRY’S experiences with the scientific advice offered by the federal joint committee within the early benefit assessment of pharmaceuticals in Germany JO - Int J Technol Assess Health Care VL - 34 UR - https://doi.org/10.1017/S0266462317004536 DO - 10.1017/S0266462317004536 ID - Dintsios2018 ER - TY - JOUR AU - Busse, R. AU - Blumel, M. PY - 2014 DA - 2014// TI - Germany: health system review JO - Health Syst Transit VL - 16 ID - Busse2014 ER - TY - STD TI - General Methods. Version 5.0 of 10 July 2017. [Internet]. 2017. Available from: https://www.iqwig.de/download/General-Methods_Version-5-0.pdf. UR - https://www.iqwig.de/download/General-Methods_Version-5-0.pdf ID - ref5 ER - TY - JOUR AU - Skipka, G. AU - Wieseler, B. AU - Kaiser, T. AU - Thomas, S. AU - Bender, R. AU - Windeler, J. PY - 2016 DA - 2016// TI - Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs JO - Biom J VL - 58 UR - https://doi.org/10.1002/bimj.201300274 DO - 10.1002/bimj.201300274 ID - Skipka2016 ER - TY - BOOK PY - 2011 DA - 2011// TI - Validity of surrogate endpoints in oncology. Version 1.1 PB - IQWiG CY - Cologne ID - ref7 ER - TY - BOOK AU - Röhmel, J. PY - 2012 DA - 2012// TI - Gutachten zum Vorschlag des IQWiG zur Bewertung des Ausmaßes des Zusatznutzens im Rahmen der Nutzenbewertung von Arzneimitteln nach §35a SGB V ID - Röhmel2012 ER - TY - JOUR AU - Witte, J. AU - Greiner, W. PY - 2013 DA - 2013// TI - Problembefunde der Quantifizierung des Zusatznutzens im Rahmen der frühen Arzneimittelnutzenbewertung JO - Gesundh ökon Qual Manag. VL - 18 UR - https://doi.org/10.1055/s-0033-1350539 DO - 10.1055/s-0033-1350539 ID - Witte2013 ER - TY - JOUR AU - Vach, W. PY - 2014 DA - 2014// TI - Quantifying the additional clinical benefit of new medicines: little - considerable - significant - 6 remarks from a biometrician's point of view JO - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) VL - 76 UR - https://doi.org/10.1055/s-0033-1363682 DO - 10.1055/s-0033-1363682 ID - Vach2014 ER - TY - JOUR AU - Herpers, M. AU - Dintsios, C. M. PY - 2019 DA - 2019// TI - Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany JO - Eur J Health Econ VL - 20 UR - https://doi.org/10.1007/s10198-018-0981-3 DO - 10.1007/s10198-018-0981-3 ID - Herpers2019 ER - TY - BOOK AU - NutzenV, A. M. PY - 2010 DA - 2010// TI - Verordnung über die Nutzenbewertung von Arzneimitteln nach § 35a Absatz 1 SGB V für Erstattungsvereinbarungen nach § 130b SGB V ID - NutzenV2010 ER - TY - BOOK PY - 2011 DA - 2011// TI - Supplement to the FJC rules of procedure. Chapter 5. [German] ID - ref13 ER - TY - JOUR AU - Niehaus, I. AU - Dintsios, C. M. PY - 2018 DA - 2018// TI - Confirmatory versus explorative endpoint analysis: decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs JO - Health Policy VL - 122 UR - https://doi.org/10.1016/j.healthpol.2018.03.017 DO - 10.1016/j.healthpol.2018.03.017 ID - Niehaus2018 ER - TY - JOUR AU - Ruof, J. AU - Knoerzer, D. AU - Dünne, A. A. AU - Dintsios, C. M. AU - Staab, T. AU - Schwartz, F. W. PY - 2014 DA - 2014// TI - Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany JO - Health Policy VL - 118 UR - https://doi.org/10.1016/j.healthpol.2014.08.004 DO - 10.1016/j.healthpol.2014.08.004 ID - Ruof2014 ER - TY - JOUR AU - Ruof, J. AU - Schwartz, F. W. AU - Schulenburg, J. M. AU - Dintsios, C. M. PY - 2014 DA - 2014// TI - Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation JO - Eur J Health Econ VL - 15 UR - https://doi.org/10.1007/s10198-013-0495-y DO - 10.1007/s10198-013-0495-y ID - Ruof2014 ER - TY - JOUR AU - Peinemann, F. AU - Labeit, A. PY - 2019 DA - 2019// TI - Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: a study based on federal joint committee data JO - J Evid Based Med VL - 12 UR - https://doi.org/10.1111/jebm.12340 DO - 10.1111/jebm.12340 ID - Peinemann2019 ER - TY - BOOK PY - 2016 DA - 2016// TI - Framework agreement between the National Association of SHI Funds and Pharmaceutical Companies Associations [in German] ID - ref18 ER - TY - JOUR AU - Mahlich, J. AU - Sindern, J. AU - Suppliet, M. PY - 2018 DA - 2018// TI - Cross-national drug price comparisons with economic weights in external reference pricing in Germany JO - Expert Rev Pharmacoecon Outcomes Res VL - 19 ID - Mahlich2018 ER - TY - JOUR AU - Rasch, A. AU - Dintsios, C. M. PY - 2015 DA - 2015// TI - Subgroups in the early benefit assessment of pharmaceuticals: a methodical review JO - Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen VL - 109 UR - https://doi.org/10.1016/j.zefq.2015.01.001 DO - 10.1016/j.zefq.2015.01.001 ID - Rasch2015 ER - TY - JOUR AU - Ruof, J. AU - Dintsios, C. -. M. AU - Schwartz, F. W. PY - 2014 DA - 2014// TI - Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.05.001 DO - 10.1016/j.jval.2014.05.001 ID - Ruof2014 ER - TY - JOUR AU - Ludwig, S. AU - Dintsios, C. M. PY - 2016 DA - 2016// TI - Arbitration board setting reimbursement amounts for pharmaceutical innovations in Germany when Price negations between payers and manufacturers fail: an empirical analysis of 5 Years’ experience JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.05.016 DO - 10.1016/j.jval.2016.05.016 ID - Ludwig2016 ER - TY - BOOK AU - Fricke, U. AU - Beck, T. PY - 2014 DA - 2014// TI - Neue Arzneimittel Fakten und Bewertungenn PB - Wissenschaftliche Verlagsgesellschaft CY - Stuttgart ID - Fricke2014 ER - TY - JOUR AU - Millas, C. AU - Höer, A. AU - Zimmermann, A. AU - Häussler, B. PY - 2017 DA - 2017// TI - Marktdurchdringung von neuen Arzneimitteln JO - Gesundh ökon Qual manag VL - 22 UR - https://doi.org/10.1055/s-0042-122162 DO - 10.1055/s-0042-122162 ID - Millas2017 ER - TY - JOUR AU - Sullivan, S. D. AU - Mauskopf, J. A. AU - Augustovski, F. AU - Jaime Caro, J. AU - Lee, K. M. AU - Minchin, M. PY - 2014 DA - 2014// TI - Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2013.08.2291 DO - 10.1016/j.jval.2013.08.2291 ID - Sullivan2014 ER - TY - STD TI - Eurostat, cartographer Eurostat. Statistical office of the European Union. ID - ref26 ER - TY - STD TI - Danish Medicines Agency. Lægemidlerstyrelsen. [Internet]. [cited 09 April 2018]. Available from: http://www.medicinpriser.dk. UR - http://www.medicinpriser.dk ID - ref27 ER - TY - STD TI - Hauptverband der österreichischen Sozialversicherungsträger. Erstattungskodex. [Internet]. [cited 09 April 2018]. Available from: http://www.hauptverband.at/cdscontent/?contentid=10007.693707. UR - http://www.hauptverband.at/cdscontent/?contentid=10007.693707 ID - ref28 ER - TY - STD TI - Kela. Medicinal products database. [Internet]. [cited 09 April 2018]. Available from: https://easiointi.kela.fi/laakekys_app/LaakekysApplication?kieli=en. UR - https://easiointi.kela.fi/laakekys_app/LaakekysApplication?kieli=en ID - ref29 ER - TY - STD TI - TLV. Dental and Pharmaceutical Benefits Agency. Databas läkemedel. [Internet]. [cited 09 April 2018]. Available from: https://www.tlv.se/beslut/sok-i-databasen.html. UR - https://www.tlv.se/beslut/sok-i-databasen.html ID - ref30 ER - TY - STD TI - Zorginstituut Nederland. Medicijnkosten. [Internet]. [cited 09 April 2018]. Available from: http://www.medicijnkosten.nl. UR - http://www.medicijnkosten.nl ID - ref31 ER - TY - JOUR AU - Schlander, M. AU - Dintsios, C. M. AU - Gandjour, A. PY - 2018 DA - 2018// TI - Budgetary impact and cost drivers of drugs for rare and Ultrarare diseases JO - Value Health VL - 21 UR - https://doi.org/10.1016/j.jval.2017.10.015 DO - 10.1016/j.jval.2017.10.015 ID - Schlander2018 ER - TY - JOUR AU - Dabisch, I. AU - Dethling, J. AU - Dintsios, C. M. AU - Drechsler, M. AU - Kalanovic, D. AU - Kaskel, P. PY - 2014 DA - 2014// TI - Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany JO - Heal Econ Rev VL - 4 UR - https://doi.org/10.1186/2191-1991-4-2 DO - 10.1186/2191-1991-4-2 ID - Dabisch2014 ER - TY - STD TI - Isbary G, Staab TR, Amelung VE, Dintsios CM, Iking-Konert C, Nesurini SM, et al. The effect of crossover in oncology clinical trials on evidence levels in early benefit assessment in Germany. Value Health. 2017 21:698-706. ID - ref34 ER - TY - JOUR AU - Hammerschmidt, T. PY - 2017 DA - 2017// TI - Analyse der AMNOG-Erstattungsbeträge im europäischen Preisumfeld JO - Gesundh ökon Qual Manag VL - 22 ID - Hammerschmidt2017 ER - TY - JOUR AU - Lauenroth, V. D. AU - Stargardt, T. PY - 2017 DA - 2017// TI - Pharmaceutical pricing in Germany: how is value determined within the scope of AMNOG? JO - Value Health VL - 20 UR - https://doi.org/10.1016/j.jval.2017.04.006 DO - 10.1016/j.jval.2017.04.006 ID - Lauenroth2017 ER - TY - JOUR AU - Radic, D. AU - Haugk, S. AU - Radic, M. PY - 2018 DA - 2018// TI - Benefit assessment and price negotiation under AMNOG: calculable process or unfair poker game? JO - Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) VL - 80 ID - Radic2018 ER - TY - STD TI - Bausch J, Bruns J, Kaesbach W, Maywald U, Schmidt P, Ulrisch V, et al. WIRKSTOFFKOMBINATIONEN qualitative und monetäre Herausforderungen. Ein aktueller Diskussionsbeitrag mit konkreten Lösungsansätzen. 2016. p. 1–21. ID - ref38 ER - TY - JOUR AU - Theidel, U. AU - Schulenburg, J. M. PY - 2016 DA - 2016// TI - Benefit assessment in Germany: implications for price discounts JO - Heal Econ Rev VL - 6 UR - https://doi.org/10.1186/s13561-016-0109-3 DO - 10.1186/s13561-016-0109-3 ID - Theidel2016 ER - TY - JOUR AU - Theidel, U. AU - Löpmeier, J. AU - Mittendorf, T. PY - 2016 DA - 2016// TI - Impact of trial design on Price discounts after early benefit assessment (AMNOG) in Germany JO - Value Health VL - 19 UR - https://doi.org/10.1016/j.jval.2016.09.898 DO - 10.1016/j.jval.2016.09.898 ID - Theidel2016 ER - TY - JOUR AU - Theidel, U. AU - Wahlers, K. AU - Mittendorf, T. PY - 2014 DA - 2014// TI - PCN176 - Amnog benefit assessment for oncologic and orphan drugs in Germany – implications for Price discounts JO - Value Health VL - 17 UR - https://doi.org/10.1016/j.jval.2014.08.2335 DO - 10.1016/j.jval.2014.08.2335 ID - Theidel2014 ER - TY - JOUR AU - Beckert, U. AU - Vorwerk, H. AU - Löpmeier, J. AU - Kulp, W. PY - 2017 DA - 2017// TI - PHP148 - non-quantifiable benefit within the German Amnog system: factors contributing to time limits set for benefit resolutions and potential implications on Price discounts JO - Value Health VL - 20 UR - https://doi.org/10.1016/j.jval.2017.08.1680 DO - 10.1016/j.jval.2017.08.1680 ID - Beckert2017 ER -